Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Saved in:
| Title: | Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. |
|---|---|
| Authors: | Louveau B; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France., Resche-Rigon M; Department of Biostatistics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U1153, Saint Louis Hospital APHP, Paris, France., Lesimple T; Oncodermatology Unit, Eugene Marquis Center, CHU CLCC, Rennes, France., Da Meda L; Department of Dermatology, Saint Louis Hospital APHP, Paris, France.; Centre d'Investigation Clinique (CIC 1427), Saint Louis Hospital APHP, Paris, France., Pracht M; Oncodermatology Unit, Eugene Marquis Center, CHU CLCC, Rennes, France., Baroudjian B; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France., Delyon J; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France., Amini-Adle M; CHU Lyon, Lyon, France., Dutriaux C; INSERM U1035, Université de Bordeaux, Bordeaux, France., Reger de Moura C; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France., Sadoux A; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France., Jouenne F; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France., Ghrieb Z; Centre d'Investigation Clinique (CIC 1427), Saint Louis Hospital APHP, Paris, France., Vilquin P; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France., Bouton D; DRCI, APHP, Paris, France., Tibi A; AGEPS, APHP, Paris, France., Huguet S; Institut Curie, Saint Cloud, France., Rezai K; Institut Curie, Saint Cloud, France., Battistella M; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Pathology, APHP Saint Louis Hospital, Paris, France., Mourah S; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France., Lebbe C; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France. celeste.lebbe@aphp.fr.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 15; Vol. 27 (14), pp. 3876-3883. Date of Electronic Publication: 2021 May 04. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33947696 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF <superscript>V600MUT</superscript> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Louveau+B%22">Louveau B</searchLink>; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Resche-Rigon+M%22">Resche-Rigon M</searchLink>; Department of Biostatistics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U1153, Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Lesimple+T%22">Lesimple T</searchLink>; Oncodermatology Unit, Eugene Marquis Center, CHU CLCC, Rennes, France.<br /><searchLink fieldCode="AU" term="%22Da+Meda+L%22">Da Meda L</searchLink>; Department of Dermatology, Saint Louis Hospital APHP, Paris, France.; Centre d'Investigation Clinique (CIC 1427), Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Pracht+M%22">Pracht M</searchLink>; Oncodermatology Unit, Eugene Marquis Center, CHU CLCC, Rennes, France.<br /><searchLink fieldCode="AU" term="%22Baroudjian+B%22">Baroudjian B</searchLink>; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Delyon+J%22">Delyon J</searchLink>; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Amini-Adle+M%22">Amini-Adle M</searchLink>; CHU Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Dutriaux+C%22">Dutriaux C</searchLink>; INSERM U1035, Université de Bordeaux, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Reger+de+Moura+C%22">Reger de Moura C</searchLink>; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sadoux+A%22">Sadoux A</searchLink>; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Jouenne+F%22">Jouenne F</searchLink>; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Ghrieb+Z%22">Ghrieb Z</searchLink>; Centre d'Investigation Clinique (CIC 1427), Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Vilquin+P%22">Vilquin P</searchLink>; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bouton+D%22">Bouton D</searchLink>; DRCI, APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Tibi+A%22">Tibi A</searchLink>; AGEPS, APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Huguet+S%22">Huguet S</searchLink>; Institut Curie, Saint Cloud, France.<br /><searchLink fieldCode="AU" term="%22Rezai+K%22">Rezai K</searchLink>; Institut Curie, Saint Cloud, France.<br /><searchLink fieldCode="AU" term="%22Battistella+M%22">Battistella M</searchLink>; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.; Department of Pathology, APHP Saint Louis Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Mourah+S%22">Mourah S</searchLink>; Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital APHP, Paris, France.; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Lebbe+C%22">Lebbe C</searchLink>; Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI), Saint Louis Hospital APHP, Paris, France. celeste.lebbe@aphp.fr.; Department of Dermatology, Saint Louis Hospital APHP, Paris, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2021 Jul 15; Vol. 27 (14), pp. 3876-3883. <i>Date of Electronic Publication: </i>2021 May 04. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33947696 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1158/1078-0432.CCR-20-4050 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 3876 Titles: – TitleFull: Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Louveau B – PersonEntity: Name: NameFull: Resche-Rigon M – PersonEntity: Name: NameFull: Lesimple T – PersonEntity: Name: NameFull: Da Meda L – PersonEntity: Name: NameFull: Pracht M – PersonEntity: Name: NameFull: Baroudjian B – PersonEntity: Name: NameFull: Delyon J – PersonEntity: Name: NameFull: Amini-Adle M – PersonEntity: Name: NameFull: Dutriaux C – PersonEntity: Name: NameFull: Reger de Moura C – PersonEntity: Name: NameFull: Sadoux A – PersonEntity: Name: NameFull: Jouenne F – PersonEntity: Name: NameFull: Ghrieb Z – PersonEntity: Name: NameFull: Vilquin P – PersonEntity: Name: NameFull: Bouton D – PersonEntity: Name: NameFull: Tibi A – PersonEntity: Name: NameFull: Huguet S – PersonEntity: Name: NameFull: Rezai K – PersonEntity: Name: NameFull: Battistella M – PersonEntity: Name: NameFull: Mourah S – PersonEntity: Name: NameFull: Lebbe C IsPartOfRelationships: – BibEntity: Dates: – D: 15 M: 07 Text: 2021 Jul 15 Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1557-3265 Numbering: – Type: volume Value: 27 – Type: issue Value: 14 Titles: – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research Type: main |
| ResultId | 1 |
